Clinical Trial

Intravitreal Topotecan in the Repair of Rhegmatogenous Retinal Detachment with Proliferative Vitreoretinopathy

Study acronym: TOPO-RD
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 11, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
Intravitreal topotecan has anti-inflammatory, anti-proliferative and anti-fibrotic activity that we hypothesize may exhibit high efficacy for the treatment of proliferative vitreoretinopathy (PVR) in patients with rhegmatogenous retinal detachment (RRD). A high efficacy for intravitreal topotecan has been exhibited in cell cultures of PVR. At the same time, intravitreal topotecan has been routinely used in the treatment of vitreous seeds from retinoblastoma. At doses of 5-30 micrograms per injection, no adverse events have been reported with the use of intravitreal topotecan. Therefore, the current prospective matched phase II trial aims to investigate the efficacy and safety of intravitreal topotecan for severe PVR in patients with RRD.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-08-29; most recent amendment 2025-02-07.
Status change: Not Yet Recruiting → Recruiting 2023-02-27
Trial Details
NCT Number NCT05523869
Lead Sponsor Unity Health Toronto
Conditions Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment
Enrollment 50 participants
Start Date 2023-02-23
Primary Completion 2026-02 (estimated)
Study Completion 2026-02 (estimated)
Updated on ClinicalTrials.gov 2025-02-11